Landmark Imaging System Sale

Paraytec Ltd have sold their 50th ActiPix UV Imaging System. This milestone sale was achieved in a new applications area for Paraytec in the pharmaceutical industry. Paraytec’s latest system, the SDI300 allows  pharmaceutical formulators to directly image drugs dissolving from a tablet surface, to enable more complete understanding of the drug behaviour in the body.

This 50th system was sold in the United States by Paraytec’s distribution partner, Distek Inc, to a large pharmaceutical company in California. The addition of this system to their laboratory will enable the scientists to avoid pitfalls in the development process, by providing essential understanding of an API (Active Pharmaceutical Ingredient) at an earlier stage than possible with traditional dissolution techniques.

Jeff Seely, Global Manager, Sales, Marketing & Technical Service for Distek, Inc said of the SDI300 system: “The new dimension the SDI300 brings to pharmaceutical API testing further enhances our offering to our customers.”

Mark Vaux of Paraytec Ltd, commented: “The in-depth knowledge Distek has of the US pharmaceutical industry enables the rapid uptake of Paraytec’s technology, as we move towards having multiple systems in the major pharmaceutical companies.” The SDI300 is designed to provide key drug dissolution information on the new generation of sparingly soluble drug types, which require a new approach in formulation science.